Why the study?
Despite advances, significant therapeutic gaps remain for PAH, with delayed translation of innovative therapies potentially related to flawed preclinical research methodologies.
Improving the rigor and design of preclinical pulmonary hypertension studies is essential to bridge the translational gap and develop innovative therapies for PAH.
Answers are grounded in this paper and cite their sources.
Preclinical pulmonary hypertension data warrant clinical caution; leaves open refined trial designs to strengthen translational value in PAH.
Despite advances in our understanding of the disease, significant therapeutic gaps remain for pulmonary arterial hypertension (PAH). Indeed, no cure exists yet for this devastating disease, and very few innovative therapies beyond the traditional pathways of endothelial dysfunction have reached late clinical trial phases in PAH. While there are inherent limitations to the currently available animal models of PAH, the delayed translation of innovative therapies to the clinic may also relate to flawed preclinical research methodologies. The present article discusses the limitations and flaws in the design of preclinical PH trials and discusses opportunities to create preclinical studies with improved predictive value in identifying key mechanisms involved in PAH development and progression and guiding early phase drug development in PAH patients. The implementation of rigorous study design will need support not only from researchers, peer reviewers, and editors, but also from academic institutions, funding agencies, and animal ethics authorities.
No takes yet. Share an insight, caveat, or question.
Shimauchi et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: